Published in:
14-03-2022 | Hepatocellular Carcinoma | Original Article
Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018
Published in: Digestive Diseases and Sciences | Issue 8/2022
Login to get accessAbstract
Background and Aims
The burden of hepatocellular carcinoma (HCC) is increasing, and certain groups may be at higher risk.
Methods
We analyzed trends in HCC-related mortality in the USA (1999–2018) using national death data. Age-adjusted trends in death rates (annual percentage change, APC) were calculated using joinpoint regression analysis.
Results
HCC-related death rates increased by 2.1% (95% CI 1.9 to 2.3) annually. Hepatitis C (HCV)-related HCC death rates increased from 1999 to 2012 (8.9%, 95% CI 7.6 to 10.2) followed by a −1.3% (95% CI −3.5 to 0.9) decrease annually. For adults > 65 years, HCV-related HCC death rates increased (7.3% annually, 95% CI 6.5 to 8.1), especially for rural areas (11.1% annually, 95% CI 6.9 to 15.5) with high rates among African-Americans and Hispanics. Increases in non-HCV-related HCC death rates were larger: 13.5% annually (95% CI 3.6 to 24.3, 2005–2010) followed by 4.2% annually (95% CI 2.3 to 6.2, 2010–2018). Annual rates of increase were similar for men (6.8%, 95% CI 5.9 to 7.8) and women (7.0%, 95% CI 5.5 to 8.4) from 1999 to 2018. Rate of increase across races was Whites 8.3% (95% CI 7.2 to 9.4, 1999–2018), African-Americans 11.2% (95% CI −6.6 to 32.3, 2015–2018), and Hispanics 3.7% (95% CI 1.0 to 6.5, 2012–2018).
Conclusion
HCC-related mortality has increased, driven by increases in non-HCV-related mortality with important demographic and regional trends. In addition, HCV-HCC mortality remains high particularly in older persons and those in rural areas despite advances in HCV therapy. These data underscore the need for targeted approaches to mitigate the burden of HCC-related mortality similar to efforts for other cancers.